Kornimate/medical-research-clean huggingface dataset:
hysteroscopic intrauterine suturing

Conditions: Niche; Uterine Disease

Summary: clinical trial the aim of the study is to evaluate the safety and feasibility of intrauterine suturing with apollos x-tack, inserted into the uterus by hysteroscope. primary outcome: intrauterine suture will sustain the procedure - when the uterus will be opened the suture will be observed. secondary outcome: procedure complications. study design interventional pilot study study group: women undergoing laparoscopic hysterectomy.

introduction: a hysteroscopy is a procedure used to examine and treat the inside of the uterus. apollo x-tack is an endoscopic apparatus for stomach defect closure by gastroscopy. the aim of this study is to evaluate the safety and feasibility of intrauterine suturing with apollos x-tack inserted into the uterus by hysteroscope. study design interventional pilot study study group: women undergoing laparoscopic hysterectomy. inclusion criteria: benign indication for hysterectomy exclusion from the study: evidence or suspicious for malignancy sample size calculation: pilot study of 2 patients. primary outcome: intrauterine suture will sustain the procedure - when the uterus will be opened the suture will be observed. secondary outcome: procedure complications. recruitment: the recruitment of the patients will be done at the gynecology department before the surgery. procedure: after general anesthesia and entering the abdomen with the laparoscope, truclear hysteroscope with x-tack attached will be inserted to the uterine cavity. insertion of normal saline to the cavity and applying 4 points suturing to the uterus. the procedure will be monitored by external laparoscopic camera located in the abdominal cavity. after the hysterectomy the uterus will be opened and the suture will be examine. a preoperative intrauterine incision using a hysteroscope, followed by suturing, will be considered based on the success of the first procedure. crf: demographics information, obstetrics and gynecology information, surgery type, surgery indication. procedure duration, success, amount of fluid used, cervical dilatation, complications.

Eligibility criteria:
inclusion criteria: * benign indication for hysterectomy exclusion criteria: * evidence or suspicious for malignancy
phase ii study of cap-232 in patients with refractory metastatic renal cell carcinoma

Conditions: Carcinoma, Renal Cell

Summary: the purpose of this study was to evaluate the safety and efficacy of cap-232 in the treatment of patients with previously treated (refractory) renal cell carcinoma

this was a multi-center, open label, single arm study. approximately 40 patients were initially planned to be recruited. each patient was to receive a treatment cycle consisting of cap-232 via continuous iv infusion over 21 days at 0.48 mg/kg/day followed by a 7-day rest period. treatment cycles to be repeated in the absence of disease progression or unacceptable toxicity. quality of life questionnaires were to be administered at baseline, after each visit and at the end of the study. signs and symptoms of adverse events were closely monitored during treatment cycles. safety laboratory measures were done at screening, during the 72hr hospitalization (first cycle), at every interim visit , and at the end of the study. a follow-up safety visit was to be scheduled at least 30 days after the end of treatment. cap-232 plasma levels were also determined.

Eligibility criteria:
inclusion criteria: * histologically confirmed stage iv kidney clear cell carcinoma. * confirmed progressive disease after receiving a previous systemic therapy, including at least one line of standard of care. * measurable disease * age \>18 years. * life expectancy of greater than 3 months. * at least 5 years free of any other cancer(s). basal cell carcinoma, provided that is neither infiltrating nor sclerosing and carcinoma in situ of the cervix, is acceptable. * ecog performance status 2 or lower (karnofsky 60%). * normal organ and marrow function * adequate contraception prior to study entry and for the duration of study participation. * ability to understand and have the willingness to sign a written informed consent document. * ability to receive central vein access catheter and manage an infusion pump. * women of child bearing potential must have a negative serum pregnancy test. exclusion criteria: * anti-cancer therapy within 4 weeks prior to entering the study * investigational agents less than 30 days prior to enrollment in the study. * known brain metastases * history of allergic reactions attributed to compounds of similar composition to cap-232. * past or current cancer other than kidney cancer, except for: curatively treated non-melanoma skin cancer, in situ carcinoma of the cervix, other cancer curatively treated and with no evidence of disease for at least 5 years * uncontrolled intercurrent illness /social situations that would limit compliance with study requirements. * breastfeeding * patients previously enrolled into this study and subsequently withdrawn

Keywords: refractory clear cell renal cell carcinoma phase ii thallion tln-232 cap-232 m2pk
a randomised, double-blind, placebo-controlled trial to assess safety, tolerability and pharmacokinetics of liraglutide in obese adolescent subjects aged 12 to 17 years

Conditions: Metabolism and Nutrition Disorder; Obesity

Summary: this trial is conducted in europe. the purpose of the trial is to assess safety, tolerability and pharmacokinetics (the exposure of the trial drug in the body) of liraglutide in obese adolescent subjects aged 12 to 17 years.


Eligibility criteria:
inclusion criteria: * subjects with tanner stage 2-5 pubertal development at time of randomisation * body mass index (bmi) corresponding to 30 kg/m\^2 or above for adults by international cut-off points and 45 kg/m\^2 or below and equal to or above 95th percentile for age and gender * fasting plasma glucose below 7.0 mmol/l (126 mg/dl) (central laboratory analysis) exclusion criteria: * subjects with clinically diagnosed secondary causes of childhood obesity such as chromosomal abnormalities (e.g. turner syndrome), syndromic obesity (e.g. prader willi syndrome) or endocrinologic disorders (e.g. cushing syndrome) * subjects with confirmed diagnosis of bulimia * subjects with tanner stage 1 development (prepubertal) * diagnosis of type 1 or type 2 diabetes mellitus as judged by the investigator * previous treatment with a glp-1 (glucagon-like peptide 1) receptor agonists (e.g. exenatide or liraglutide or other), dpp-4 (dipeptidyl peptidase-4) inhibitors, orlistat or other weight lowering medication, any antipsychotic medication or systemic corticosteroids within the last 3 months * currently using or have used within 3 months before screening for this trial: any systemic treatment that in the opinion of the investigator interferes with pk (pharmacokinetic), pd (pharmacodynamic) and safety endpoints * surgical treatment for obesity * past or current chronic or idiopathic pancreatitis, or any of the following: -amylase or lipase above 2 times unr (upper normal range), -triglycerides above 500 mg/dl, -calcium above unr, -history of gallstones (not treated by cholecystectomy) * uncontrolled treated or untreated hypertension 99th percentile for age and gender in children * history of major depressive disorder or history of other severe psychiatric disorders (e.g. schizophrenia or bipolar disorder) that could in the opinion of the investigator interfere with trial compliance or subject safety * subjects with a history of suicide attempts or history of any suicidal behaviour within the past month before entry into the trial
efficacy of sodium glucose cotransporter 2 inhibitors on non-alcoholic fatty liver disease

Conditions: Non Alcholic Fatty Liver Disease; Hepatic Steatosis; Hepatic Fibrosis; NAFLD (Nonalcoholic Fatty Liver Disease)

Summary: evaluate the effectiveness of sodium-glucose cotransporter-2 (sglt.2) inhibitors in improving hepatic steatosis and hepatic fibrosis using imaging biomarkers and histopathology in patients with non-alcoholic fatty liver disease

2.1 background (research question, available data from the literature, current strategy for dealing with the problem, rationale of the research that paves the way to the aim(s) of the work). (200-250 words max.) non-alcoholic fatty liver disease (nafld) is a leading cause of liver-related health issues worldwide, with prevalence rates reaching up to 30%.the number of cases has been steadily rising, increasing from 391.2 million in 1990 to 882.1 million in 2017. nafld is often linked to one or more components of metabolic syndrome, such as hypertension, dyslipidemia, obesity, and type 2 diabetes mellitus, along with insulin resistance. although the exact pathogenesis of nafld is not fully understood, there is increasing evidence that insulin resistance and lipid metabolism dysregulation play significant roles in the development of hepatic steatosis. factors such as a high-fat diet, insulin resistance, obesity, and dysregulated peripheral lipolysis contribute to the increased influx of free fatty acids into the liver, leading to a 'lipotoxic' state within hepatocytes.the accumulation of triacylglycerol in the cytoplasm of hepatocytes manifests histologically as steatosis. persistent micro-hepatic injury eventually results in endoplasmic reticulum stress and mitochondrial dysfunction, which then contribute to lobular inflammation, cellular apoptosis, and hepatic fibrosis over time. if left untreated, this manageable condition can lead to serious complications, including advanced cirrhosis, hepatocellular carcinoma, and potentially cardiovascular morbidity.and mortality.given the serious prognostic implications of nafld, effective treatment is essential to prevent disease progression. while weight loss and lifestyle modifications are the primary treatments, pharmacologic options remain limited. recently, the potential of a novel oral hypoglycemic agent known as sodium-glucose cotransporter 2 (sglt-2) inhibitors in the treatment of nafld has been explored through various animal studies on rodent models and human clinical trials, showing promising effects.

Eligibility criteria:
inclusion criteria: * age \>18 years * both sex exclusion criteria: * alcohol drinker * any cause of liver affection (hepatitis, autoimmune...etc) * patients with kidney function affection

Keywords: nafld non alcoholic fatty liver disease hepatic steatosis hepatic fibrosis na glucose cotransporter 2 inhibitors sglt-2 inhibitors
the effects of cannabidiol and homotaurine in patients with mild cognitive impairment

Conditions: Mild Cognitive Impairment

Summary: a randomized clinical trial that will compare the effects of cannabidiol and homotaurine in cognition and mental health in patients with mild cognitive impairment and apoe ε4 carriers. ninety patients will be recruited and they will be randomly distributed in three groups. the first group will receive treatment with cannabidiol 5%, the second group will receive treatment with vivimind and the third group will not receive any treatment. the three groups will be compared by using an extensive neuropsychological examination and biomarkers' results from cerebrospinal fluid and blood


Eligibility criteria:
inclusion criteria: * diagnosis of mild cognitive impairment * carry apoe ε4 gene exclusion criteria: * diagnosis of dementia * patients who receive medication for memory or depression * patients who do not carry apoe ε4 gene

Keywords: cannabidiol homotaurine mild cognitive impairment cognition mental health
the influence of aerobic endurance training after roux-en-y-gastric bypass

Conditions: Morbid Obesity

Summary: the aim of this study was to assess the efficiency of aerobic physical exercise (ape) on weight loss, body composition and co-morbidities in patients after laparoscopic roux-en-y gastric bypass (rygbp).

the only effective treatment for patients with morbid obesity is bariatric surgery. sudden weight loss following bariatric operations for morbid obesity, such as roux-en-y gastric bypass (rygbp) can result in a concurrent decrease in lean body mass. however the long-time results (weight reduction, elimination co-morbidities) are depending on the post operative treatment. aerobic physical exercising (ape) is well accepted in conservative treatment of obesity as well as of diabetes mellitus type 2 (dm). the aim of this study was to assess the efficiency of ape on weight loss, body composition and co-morbidities in patients after laparoscopic roux-en-y gastric bypass (rygbp).

Eligibility criteria:
inclusion criteria: * obesity who iii exclusion criteria: * contraindications of aerobic endurance training

Keywords: bariatric surgery co-morbidities aerobic physical exercise
liver regeneration after liver resection

Conditions: Liver Diseases; Hepatectomy

Summary: the aim of this study is to characterize kupffer cell activity and activation of the innate immune response in the early phase of liver regeneration after right hepatectomy. the investigators hypothesise that liver regeneration after right hepatectomy in humans is associated with kupffer cell activation and initiation of the innate immune response and that impaired liver regeneration, liver failure and sepsis following liver resection are associated with kupffer cell dysfunction and an impaired innate immune response. the objectives for this study are to characterise kupffer cell activity and the innate immune response in human liver before and after right hepatectomy.


Eligibility criteria:
inclusion criteria: * patients requiring right hepatectomy for colorectal liver metastases exclusion criteria: * age \>75, neoadjuvant chemotherapy, recurrent disease

Keywords: liver regeneration innate immune response
hfnc vs. niv in acute copd exacerbations

Conditions: COPD Exacerbations; Acute Hypercapnic Respiratory Failure; Respiratory Failure

Summary: the investigators investigated the efficacy and safety of high flow nasal cannula (hfnc) at different flow rates compared to non-invasive ventilation (niv) in patients presenting to the emergency department (ed) with acute exacerbations of chronic obstructive pulmonary disease (copd) who did not respond adequately to bronchodilator therapy and continued to exhibit hypercapnic respiratory failure. specifically, the investigators tested the hypothesis that hfnc would be more effective at reducing partial pressure of carbon dioxide (paco2) levels and hospital stay duration and would be associated with greater patient comfort than niv.

the patients were divided randomly into one of three study groups: niv, hfnc-30, and hfnc-50. the investigators collected patient data, including demographic characteristics (age and sex), vital signs upon admission (systolic blood pressure \[sbp\], respiratory rate \[rr\], and heart rate \[hr\]), complaints and symptoms upon admission, initial arterial blood gas parameters (e.g., ph, paco2, lactate, and bicarbonate), length of stay, ed revisits, patient satisfaction, intubation status, and clinical outcomes (hospitalization, admission to the intensive care unit \[icu\], or 28-day mortality). changes in arterial blood gas parameters (e.g., δph, δpaco2, δlactate, and δbicarbonate) before treatment vs. 30, 60, and 120 minutes after treatment were recorded using a pre-prepared case data form.

Eligibility criteria:
inclusion criteria: - patients age ≥18 years with a confirmed diagnosis of copd who presented to the ed with exacerbations that did not respond to bronchodilator therapy exclusion criteria: * patients aged younger than 18 years * patients had an arterial ph ≤ 7.25; * patients were in cardiopulmonary arrest; * patients had unstable cardiac arrhythmias or hemodynamic instability; * patients showed persistent hypoxemia despite supplemental oxygen therapy; * patients were unconscious or uncooperative; * patients could not protect their airway or manage secretions; * patients had cardiogenic pulmonary edema, active hemoptysis, pneumothorax, recent upper respiratory tract/esophagus surgery, significant airway obstruction (e.g., laryngeal mass or tracheal tumor), active upper gastrointestinal bleeding, or facial trauma or deformities

Keywords: high-flow nasal cannula noninvasive ventilation copd exacerbations efficacy safety
avacen hand heating on fasting blood glucose

Conditions: Hyperglycemia; Hypertension

Summary: a double-blind crossover randomized controlled trial to investigate the effects of the avacen device on fasting blood glucose. the avacen device creates negative pressure around the hand while heating the palm. two sham devices, one providing heat but no vacuum and one providing neither heat nor vacuum were also used. each subject was tested while using each of these three devices on separate visits. subjects arrived in the morning following an overnight fast. fasting blood glucose, blood pressure, tympanic temperature, and subjective thermal ratings were measured before and throughout the 30 minutes that the device was used.


Eligibility criteria:
inclusion criteria: * healthy subjects exclusion criteria: * diabetes diagnosis, diabetes medication, blood pressure medication
effect of vitamin d deficiency on the structure of titanium platelet-rich fibrin

Conditions: PRF; Vitamin D Deficiency; Vitamin Deficiency

Summary: abstract the aim of the study was to compare the macroscopic properties, chemical degradation levels, and fibrin network structures of t-prf membranes obtained from systemically healthy individuals with optimal vitamin d levels, with vitamin d-deficient individuals who reached optimal levels after three months of vitamin d supplementation. a total of 48 participants, 24 with vitamin d deficiency and 24 with optimal vitamin d levels, were included in the study. the macroscopic properties (weight, width, length, density), chemical degradation levels and fibrin network structures of the obtained t-prf membranes were evaluated using scanning electron microscopy (sem) and light microscopy.

blood samples taken from individuals with the help of a 20 ml syringe were immediately transferred to 2 10 ml titanium tubes and placed opposite each other to ensure balance in the tabletop centrifuge device in order to be properly separated in the centrifuge process. to obtain t-prf, it was centrifuged in the intraspin™ device at 2700 rpm centrifugal force for 12 minutes. after centrifugation, the fibrin in the middle of the 3 layers formed in the titanium tube was held and pulled with the help of a press. then, the red layer in the lower layer, where erythrocytes were dense, was separated from the fibrin layer with the help of scissors and the membrane was obtained by pressing for 2 minutes using the own weight of the prf box.

Eligibility criteria:
inclusion criteria: * individuals aged 20-55 * being systemically healthy * not using any medication regularly * not taking additional vitamin d from outside * patients who met the conditions of not having used antibiotics for the last three months were included in the study. exclusion criteria: * people who use cigarettes (tobacco) and alcohol * those with platelet function and clotting disorders * those who are pregnant or breastfeeding * those who use medications that affect the natural clotting process * those with a history of infection in the last three months * those receiving immunosuppressive therapy * those who do not consent to volunteer
effectiveness of mineral trioxide aggregate and platelet rich fibrin along with biodentine. .

Conditions: Pulpitis - Irreversible

Summary: the aim of this study was to clinically and radiographically evaluate the effectiveness of mta, biodentine, platelet rich fibrin along with mineral trioxide aggregate and platelet rich fibrin along with biodentine as pulpotomy medicament in patients with pulpitis.

sixty systemically healthy patients with irreversible pulpitis were enrolled in the study based on inclusion and exclusion criteria. all the enrolled patients were randomly allocated into 4 groups (15 each) group i: mta group: vital pulpotomy will be done using mineral trioxide aggregate (mta) as pulp capping agent. group ii: biodentine group: vital pulpotomy will be done using biodentine as pulp capping agent. group iii: prf + mta group: vital pulpotomy will be done using prf and mineral trioxide aggregate (mta) as pulp capping agent. group iv: prf+ biodentine group: vital pulpotomy will be done using prf and biodentine as pulp capping agent patients were assessed at 1 day,3 months, 6 months and 9 months postoperatively for pain, pulp sensitivity test, swelling or presence of any sinus tract. all the proposed teeth were assessed radiographically at1 day, 3 months, 6 months and 9 months postoperatively.

Eligibility criteria:
inclusion criteria: * patients with carious exposed tooth exhibiting clinical and radiographical evidence for pulpitis. * deep caries extending ≥2/3 of dentin. * tooth with positive response with cold testing. * tooth with no mobility. * no signs of pulpal necrosis including sinus tract or swelling. * patient approval for the treatment and follow up exclusion criteria: * any systemic disease that could influence the outcome. * non-restorable tooth. * teeth with periapical widening. * tooth which cannot be isolated. * teeth with marginal periodontitis or crestal bone loss. * indication of post/ post and core restoration marginal periodontitis with attachment loss \>5mm. * teeth with immature root or calcified canal. * teeth with internal and external resorption. * no pulp exposure after caries excavation. * uncontrolled bleeding after access cavity preparation after several minutes n * no bleeding at all at the time of access opening * pregnant or nursing women. * individual hypersensitive or allergic to any product used in the study

Keywords: pulpal regeneration pulpitis pulpotomy
chest compressor for conservative treatment of pectus carinatum: a multicenter study

Conditions: Pectus Carinatum, Chondromanubrial

Summary: pectus carinatum (pc) is a congenital deformity of the chest wall whose prevalence is 0.6% of the population and although it does not cause cardio respiratory physiological damage, it has profound psychological effects on young people. its treatment today is still primarily surgical in our country, despite the fact that conservative treatment by chest compression may be effective in the chondrogladiolar variant, which represents 90% of cases of pc. the aim of the present study is to conservatively treat a series of 60 patients using a new modular and adjustable chest compressor model to assess the effectiveness of this chest compressor in the noninvasive treatment of pc; and also assess the safety of such treatment by the rate of adverse events occurring during treatment. secondary objectives will be to evaluate the adherence that pc patients have to this type of treatment by quantifying the number of hours of use per day, besides evaluating the chest compressor and its components for durability and resistance as a device for continuous use.


Eligibility criteria:
inclusion criteria: * pectus carinatum condrogladiolar variant * no other comorbidities that could interfere with the use of compressor exclusion criteria: * marfan syndrome * active cardiovascular disease * significant scoliosis or thoracic deformity * important obesity * pectus carinatum chondromanubrial variant * poor commitment to protocol by both research participant and parents

Keywords: braces conservative treatment thoracic wall pectus carinatum